Nutriband raises $1.75M via warrants to fund AVERSA fentanyl patch
What's the deal? NutribandDealroom has a profile for this one. Try Dealroom → (NASDAQ: NTRB) raised approximately $1.75 million after holders exercised 272,671 NTRBW warrants at a strike price of $6.43. The warrants expired September 30 without extension, leaving the company with no remaining tradable warrants.
What's the endgame? Nutriband develops transdermal pharmaceutical products. Its lead candidate is AVERSA Fentanyl, an opioid patch built on the company's AVERSA abuse-deterrent technology, which aims to prevent the misuse, diversion, and accidental exposure of drugs.
Where's the money going? The proceeds will primarily fund the remaining clinical development of AVERSA Fentanyl and a New Drug Application (NDA) submission to the US Food and Drug Administration for marketing approval.
Why it matters? Nutriband describes AVERSA Fentanyl as a potential first-of-its-kind abuse-deterrent opioid patch. A 2022 Health AdvancesDealroom has a profile for this one. Try Dealroom → market analysis estimated peak annual US sales of $80 million to $200 million.
The signal: For a small-cap drug developer, closing out its warrant structure converts an outstanding obligation into capital directed at a late-stage regulatory push — a modest but concrete step toward the FDA filing that stands between AVERSA and the market.
Read more: business.thepilotnews.com
Image credit: Generated with Gemini
